The Use of Pediatric Donors in Pancreas Transplantation

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Arianna Cabrales, Rana Kumar, Christopher Webb, Emily McCracken, Colleen L. Jay, Giuseppe Orlando, Alan C. Farney, Robert J. Stratta
Natura: Artículo Open Access
Pubblicazione: Wiley 2026
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867003391202295808
author Arianna Cabrales
Rana Kumar
Christopher Webb
Emily McCracken
Colleen L. Jay
Giuseppe Orlando
Alan C. Farney
Robert J. Stratta
author_facet Arianna Cabrales
Rana Kumar
Christopher Webb
Emily McCracken
Colleen L. Jay
Giuseppe Orlando
Alan C. Farney
Robert J. Stratta
Arianna Cabrales
Rana Kumar
Christopher Webb
Emily McCracken
Colleen L. Jay
Giuseppe Orlando
Alan C. Farney
Robert J. Stratta
collection Wiley Open Access
contents The Use of Pediatric Donors in Pancreas Transplantation Arianna Cabrales Rana Kumar Christopher Webb Emily McCracken Colleen L. Jay Giuseppe Orlando Alan C. Farney Robert J. Stratta Clinical Transplantation ABSTRACT Introduction The use of pediatric donors in simultaneous pancreas‐kidney transplantation (SPKT) and solitary pancreas transplantation is not universally accepted Methods Single center retrospective review of 310 consecutive SPKTs and 50 solitary pancreas transplants performed from 11/1/01 to 1/1/25. All patients received depleting antibody induction with tacrolimus/mycophenolate/prednisone maintenance therapy. Pediatric donors were defined as age <18 years. Results In the SPKT group, 72 patients (23.2%) received organs from donors <18 years (mean 13.9 years), 215 from donors 18–40 years (mean 26.4 years), and 23 from donors >40 years of age (mean 47.4 years). Rates of early pancreas thrombosis were 5.6%, 6.5%, and 4.3% ( p = 0.51), according to increasing donor age category. One‐year death‐censored pancreas and kidney graft survival rates (GSRs) were 93.0%, 92.0%, and 90.5%; and 98.6%, 99.1%, and 95.5%, respectively (both p = NS). Four‐year death‐censored pancreas GSRs were 87.9%, 78.7%, and 90.5%, respectively ( p = 0.08). There were 11 pediatric donors ≤40 kg body weight (smallest 28 kg). One‐year patient, pancreas, and kidney GSRs were 100% and 4‐year patient and pancreas GSRs were 100% (kidney GSR 90%). There were no technical pancreas or kidney graft losses in the ≤40 kg donor group, and pancreas graft survival beyond 18 years has occurred. In 11 patients receiving solitary pancreas transplants from pediatric donors, there were no cases of early thrombosis. Conclusions Despite concerns related to small caliber vessels and donor/recipient size mismatch, pediatric donors are associated with excellent mid‐term outcomes in SPKT recipients and may not represent a contraindication to pancreas utilization in solitary pancreas transplantation. 10.1111/ctr.70575 http://creativecommons.org/licenses/by-nc/4.0/
doi_str_mv 10.1111/ctr.70575
format Artículo Open Access
id wiley_oa_10_1111_ctr_70575
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc/4.0/
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle The Use of Pediatric Donors in Pancreas Transplantation
Arianna Cabrales
Rana Kumar
Christopher Webb
Emily McCracken
Colleen L. Jay
Giuseppe Orlando
Alan C. Farney
Robert J. Stratta
Clinical Transplantation
The Use of Pediatric Donors in Pancreas Transplantation Arianna Cabrales Rana Kumar Christopher Webb Emily McCracken Colleen L. Jay Giuseppe Orlando Alan C. Farney Robert J. Stratta Clinical Transplantation ABSTRACT Introduction The use of pediatric donors in simultaneous pancreas‐kidney transplantation (SPKT) and solitary pancreas transplantation is not universally accepted Methods Single center retrospective review of 310 consecutive SPKTs and 50 solitary pancreas transplants performed from 11/1/01 to 1/1/25. All patients received depleting antibody induction with tacrolimus/mycophenolate/prednisone maintenance therapy. Pediatric donors were defined as age <18 years. Results In the SPKT group, 72 patients (23.2%) received organs from donors <18 years (mean 13.9 years), 215 from donors 18–40 years (mean 26.4 years), and 23 from donors >40 years of age (mean 47.4 years). Rates of early pancreas thrombosis were 5.6%, 6.5%, and 4.3% ( p = 0.51), according to increasing donor age category. One‐year death‐censored pancreas and kidney graft survival rates (GSRs) were 93.0%, 92.0%, and 90.5%; and 98.6%, 99.1%, and 95.5%, respectively (both p = NS). Four‐year death‐censored pancreas GSRs were 87.9%, 78.7%, and 90.5%, respectively ( p = 0.08). There were 11 pediatric donors ≤40 kg body weight (smallest 28 kg). One‐year patient, pancreas, and kidney GSRs were 100% and 4‐year patient and pancreas GSRs were 100% (kidney GSR 90%). There were no technical pancreas or kidney graft losses in the ≤40 kg donor group, and pancreas graft survival beyond 18 years has occurred. In 11 patients receiving solitary pancreas transplants from pediatric donors, there were no cases of early thrombosis. Conclusions Despite concerns related to small caliber vessels and donor/recipient size mismatch, pediatric donors are associated with excellent mid‐term outcomes in SPKT recipients and may not represent a contraindication to pancreas utilization in solitary pancreas transplantation. 10.1111/ctr.70575 http://creativecommons.org/licenses/by-nc/4.0/
title The Use of Pediatric Donors in Pancreas Transplantation
topic Clinical Transplantation
url https://onlinelibrary.wiley.com/doi/10.1111/ctr.70575